Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Mizagliflozin · DSP-3235, KGA-3235

Small molecule · developed by Vogenx

Phase 2 Most advanced trial

VOGX Developer

2 Registered trials

What is Mizagliflozin?

Mizagliflozin is an investigational small-molecule drug studied in Postbariatric Hypoglycemia.

At a glance

Also known as: DSP-3235, KGA-3235
Drug type: Small molecule
Therapy area: Endocrine
Developer: Vogenx, Inc. (VOGX)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2
UNII: 1X96A704XV

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07760961	Phase 2	Postbariatric Hypoglycemia	Not yet recruiting	VOGX
NCT05721729	Phase 2	Postbariatric Hypoglycemia	Completed	VOGX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Postbariatric Hypoglycemia

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the VOGX page.

Follow VOGX, the company behind Mizagliflozin

See VOGX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

VOGX catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z